Pharmaceutical industry – Page 3
-
BusinessModerna’s mRNA vaccine approved for RSV
US approval adds complementary option to protein-based vaccines for respiratory syncytial virus
-
OpinionWill science ever reach an end?
While the rate of discoveries in any field may slow over time, the frontier creeps ever further
-
ResearchSimplified hydroformylation replaces rhodium with base metal
Bench-friendly asymmetric hydroformylation swaps toxic gas and expensive catalyst for cheap reagents and mild conditions
-
BusinessPan-cancer approval shows huge potential for antibody–drug conjugates
Enhertu gains approval based on gene expression rather than tumour location
-
ResearchHow HIV drugs have changed over the decades
From one big pill that only prolonged lives a few months, through the 20 pills a day years to modern combination therapies, treating HIV is a science success story
-
OpinionLab automation gives me more time at the top of the mountain
Getting back to the bench reminds Derek Lowe how much has changed in 40 years
-
ResearchScreening reveals thousands of ‘undrugged, yet druggable’ proteins
Collaboration involving Pfizer develops freely accessible AI tool to probe protein–compound interactions
-
ResearchCould mechanochemistry have saved Abbott Laboratories $250 million?
Ball milling solves problem of disappearing ritonavir polymorph
-
BusinessSix dead in explosion and fire at Indian pharmaceutical plant
At least 17 others injured at SB Organics facility near Hyderabad
-
OpinionWater isn’t normal
Despite its familiarity, water is a chemical oddity. But that’s what makes it fascinating
-
BusinessUS government moves to block Chinese biotechs’ operations
WuXi Apptec and others accused of national security risk, as trade groups back legislation limiting their activities
-
OpinionFrom one sinking ship to another?
Biogen abandoning Alzheimer’s antibody aducanumab is unusual, but hardly surprising, says Derek Lowe
-
OpinionMaking chemicals safe and sustainable
The green transition is an opportunity to also make industry simpler and safer
-
BusinessBig deals confirm renewed interest in radiopharmaceuticals
Acquisitions of RayzeBio and Point Biopharma highlight the potential of targeting radioactivity directly to tumour cells
-
BusinessNovo Holdings to buy contract manufacturer Catalent for $16.5 billion
Parent firm will then sell on three manufacturing sites to Novo Nordisk to boost capacity for diabetes and weight loss drugs
-
BusinessUS industry leaders repeat calls to reinstate security programme
Six month gap in vetting people with access to high-risk chemicals means potential threats may have been missed
-
OpinionHarnessing fear and greed for innovation
Many powerful emotions motivate us in the search for new knowledge
-
BusinessNew Covid-19 antiviral cuts symptoms by 1.5 days
Simnotrelvir already has emergency approval in China
-
WebinarUnlocking the future of the chemical industry: the transformative potential of biocatalysis
Learn how scientists are addressing the use of biocatalysis or chemoenzymatic catalysis within industry
-
BusinessIllumina to give up Grail as competition appeals fail
Sequencing giant will sell off its former spin-out in accordance with regulator orders